Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Dynacure studies DYN-101 in phase I/II trial for centronuclear myopathies

Jan. 27, 2020

The University of Minnesota presents psi-glutathione compounds

Jan. 27, 2020

BlackThorn initiates phase II proof-of-concept trial with BTRX-140 in major depressive disorder

Jan. 24, 2020

Anerem approved in Japan for general anesthesia

Jan. 24, 2020

Norbinaltorphimine shown efficacious for preclinical autism and ADHD

Jan. 24, 2020

Shanghai Institute of Materia Medica patents GPR84 antagonists

Jan. 24, 2020

Dayvigo approved in Japan for the treatment of insomnia

Jan. 24, 2020

Results presented from phase III PENUT study of erythropoietin in preterm infants

Jan. 24, 2020

KEA-1010 retains analgesic and sedative potency in vivo

Jan. 24, 2020

Ketamine and opioids

Jan. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...